The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 21 December 2004, www.theannals.com, DOI 10.1345/aph.1E330.
 The Annals of Pharmacotherapy: Vol. 39, No. 2, pp. 329-334. DOI 10.1345/aph.1E330
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lauderdale, S. A
Right arrow Articles by Sheehan, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lauderdale, S. A
Right arrow Articles by Sheehan, A. H.

DRUG INFORMATION ROUNDS

Intensive Lipid-Lowering Therapy in Patients with Coronary Heart Disease

Stacy A Lauderdale, PharmD

Assistant Professor of Pharmacy Practice, McWhorter School of Pharmacy, Samford University; Drug Information Specialist, Samford University Global Drug Information Service, Birmingham, AL

Amy Heck Sheehan, PharmD

Associate Professor of Pharmacy Practice, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN; Drug Information Specialist, Clarian Health Partners, Indianapolis, IN

Reprints: Dr. Lauderdale, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Dr., Birmingham, AL 35229-7027, fax 205/726-4012, salauder{at}samford.edu

OBJECTIVE: To describe current data evaluating the use of intensive lipid-lowering therapy in patients with coronary heart disease.

DATA SOURCES: A literature search using MEDLINE (1966-September 2004) was conducted using the search terms lipoproteins, low-density lipoprotein cholesterol (LDL-C), hydroxymethylglutaryl-coenzyme A reductase inhibitors, coronary arteriosclerosis, and coronary disease to identify published trials comparing the effects of intensive and conventional lipid-lowering therapy.

DATA SYNTHESIS: Intensive lipid-lowering therapy reduces LDL-C levels significantly more than conventional treatment and appears to reduce cardiovascular morbidity and mortality in patients who have recently experienced acute coronary syndrome (ACS). However, evidence suggesting clinical benefits in patients with stable coronary heart disease is currently lacking.

CONCLUSIONS: Although data are limited, patients with ACS may benefit from intensive lipid-lowering therapy. Several studies are underway to determine the appropriate role of intensive lipid-lowering therapy.

Key Words: coronary arteriosclerosis, coronary heart disease, hydroxymethylglutaryl-coenzyme A reductase inhibitors, low-density lipoprotein cholesterol

Published Online, December 21, 2004. www.theannals.com, DOI 10.1345/aph.1E330




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.